Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) develops and commercializes prescription medicines for attention deficit hyperactivity disorder (ADHD) and moderate to severe pain in the United States. Its portfolio includes Jornay PM, an evening-dosed methylphenidate stimulant for ADHD; Belbuca, a buprenorphine buccal… From the company’s description.
Over the twelve months to Sep 30, 2026, Collegium Pharmaceutical, Inc. reported revenue of $815.19M, up 7.7% from a year earlier, and net income of $38.17M. Its operating margin was 15.2%, and operations generated $338.02M in cash. In fiscal 2025, it reported revenue of $780.57M, up 23.6% from fiscal 2024, and net income of $62.87M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Collegium Pharmaceutical, Inc. does
In the company’s own words
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) develops and commercializes prescription medicines for attention deficit hyperactivity disorder (ADHD) and moderate to severe pain in the United States. Its portfolio includes Jornay PM, an evening-dosed methylphenidate stimulant for ADHD; Belbuca, a buprenorphine buccal film for persistent pain; Xtampza ER, an extended-release oxycodone formulation using the DETERx abuse-deterrent technology; the Nucynta immediate- and extended-release tapentadol products for acute and persistent pain; and Symproic, a treatment for opioid-induced constipation. Collegium commercializes its products through separate field sales forces focused on pain and ADHD, selling primarily to wholesalers that distribute to pharmacies, managed healthcare organizations and government agencies. It owns the rights to Jornay PM, Belbuca and Xtampza ER, and licenses U.S. commercialization rights for Nucynta from Grünenthal and Symproic from Shionogi. Its current portfolio reflects acquisitions of Ironshore in 2024, BioDelivery Sciences International and the Nucynta assets. In fiscal 2025, the company reported revenue of approximately $[amount not provided in supplied text]. Its website is www.collegiumpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- STOUGHTON, MA
- Fiscal year end
- December
- CIK
- 1267565
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Collegium Pharmaceutical, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Collegium Pharmaceutical, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Collegium Pharmaceutical, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Collegium Pharmaceutical, Inc.’s debt, $13.35M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.88%, maturing 2029 to 2029.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Collegium Pharmaceutical, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Collegium Pharmaceutical, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Collegium Pharmaceutical, Inc.'s last four quarterly filings that the numbers alone won't show?”